Emergent BioSolutions Inc. announced that its Board of Directors has authorized the repurchase of up to $50 million of the company’s common stock. The repurchase program is authorized to be executed on or before March 27, 2026.
This authorization reflects management's confidence in Emergent's strategy, future outlook, and cash generation capabilities as the company continues the turnaround phase of its multi-year transformation plan. The company expects its investment priorities to remain focused on driving long-term growth and profitability.
Stock repurchases may be made from time to time on the open market or in privately negotiated transactions, with the timing and amount determined by management based on market conditions and other factors. As of December 31, 2024, Emergent had approximately 54.3 million shares of common stock outstanding.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.